Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

OMER

+ Watchlist+ Portfolio

Omeros Corp.

Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$14.55
52-Week Range
$6.70 – $21.24
Market Cap
$1.04B
P/E (TTM)
16.88
EPS (TTM)
0.83
Dividend Yield
0.00%
Advanced Metrics
Price/Book
—
PEG Ratio
0.81
Return on Equity
—
Return on Assets
-12.08%
Gross Margin
66.04%
Operating Margin
-56.39%
Profit Margin
132.32%
Current Ratio
2.27
Debt/Equity
—
Total Debt
$193.80M
Free Cash Flow
$192.61M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$1.18B

Market Snapshot

About

Omeros Corporation is a biopharmaceutical company focused on therapies targeting complement-mediated diseases and central nervous system disorders. The company's products and pipeline include treatments for surgical bleeding, renal disease, and neurological conditions. Omeros markets Omidria, an ophthalmic drug used during cataract surgery.